Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Low dose of losartanDrug: Low dose of telmisartanDrug: High dose of telmisartanDrug: High dose of losartan
- Registration Number
- NCT02269176
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 330
Inclusion Criteria
- Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood pressure (DBP) ≥ 95 and < 110 mmHg, and the mean sitting valley value of systolic blood pressure (SBP) < 180 mmHg
Read More
Exclusion Criteria
- Not specified
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Losartan Low dose of losartan Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered Telmisartan Low dose of telmisartan Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered Telmisartan High dose of telmisartan Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered Losartan High dose of losartan Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
- Primary Outcome Measures
Name Time Method Changes in mean sitting valley value of DBP 8 weeks after start of treatment The valley value of blood pressure refers to the blood pressure measured prior to the next administration of antihypertensives
- Secondary Outcome Measures
Name Time Method